Provista Diagnostics, Inc., a molecular diagnostics company developing and commercializing proteomic-based diagnostic, prognostic and monitoring tests for cancers affecting women, announced it has expanded its exclusive license agreement for certain biomarker and autoantibody technologies identified by researchers Joshua LaBaer, M.D., Ph.D. and Karen Anderson, M.D., Ph.D. of the Biodesign Institute of Arizona State University. The license provides Provista with access to patents, proprietary technology, materials, processing techniques and protocols necessary for detection of certain autoantibodies and use of certain biomarkers. Continue reading→